Trial Profile
A Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of ETC-1002 Versus Placebo in Patients With Hypercholesterolemia Receiving Ongoing Statin Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bempedoic acid (Primary) ; HMG-CoA reductase inhibitors
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Esperion Therapeutics
- 06 Apr 2016 Results assessing the effect of ETC-1002 on serum low-density lipoprotein cholesterol published in the American Journal of Cardiology
- 04 Nov 2015 According to an Esperion Therapeutics media release, full results from this study will be presented at the American Heart Association (AHA) Scientific Sessions 2015.
- 10 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.